Novel electronic health record-based marker can identify at-risk transplant patients and reduce organ rejection
medicalxpress - A new multicenter study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that a novel electronic health record-based marker can help clinicians identify transplant patients at high risk for organ rejection because they are not ta…
AI Summary: Teams developed and validated an electronic‑health‑record derived marker that flags transplant recipients at elevated risk of organ rejection. The tool integrates routinely collected clinical data to trigger earlier review and intervention, promising to reduce rejection events if deployed thoughtfully within clinical workflows rather than buried in another alert pile.
Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment
esmo - Findings from the MajesTEC-9 study
AI Summary: Clinical data show teclistamab significantly improves survival for patients with multiple myeloma after one to three prior therapies. Those results have ignited discussions about moving the bispecific antibody earlier in treatment algorithms and prompted labs and clinicians to reassess sequencing strategies across relapsed and refractory myeloma.
FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.